FGFR1 and breast carcinoma: Increased FGFR1 and FGF3 expression was correlated with a poor response to anti-HER2 treatment in breast cancer patients, and this was overcome using a combination therapy of FGFR inhibitors together with lapatinib and trastuzumab [196].